Scholarlink

<p>Robotic surgery is increasingly adopted for rectal cancer management, including selected patients with locally advanced disease. We evaluated perioperative safety and medium- to long-term outcomes after robot-assisted rectal cancer surgery with multivisceral resection for cT4 rectal cancer in a single high-volume center. We retrospectively reviewed 45 consecutive patients with locally advanced rectal cancer who underwent robot-assisted surgery with multivisceral resection between April 2021 and June 2025. Demographic and clinical variables, surgical and postoperative outcomes, and pathological findings were extracted from medical records. Recurrence-free survival (RFS), overall survival, and local recurrence were assessed. The study included 45 patients (19 females) with a median age of 72 years. Postoperative complications of Clavien–Dindo grade III or higher occurred in 4 patients (8.8%). Pathologically, 21 patients (46.7%) had pT4 disease (pT4a in 2 and pT4b in 19 [42.2%]), and 39 patients (86.7%) achieved RM0 margins. The median follow-up was 23 months. Across stages I–III, RM0 resection was associated with superior 3-year RFS compared with RM1/RMX resection (74.6% vs. 33.3%, p = 0.03). Robot-assisted rectal cancer surgery combined with multivisceral resection can be performed safely, with acceptable midterm outcomes. RM0 status was linked to improved RFS, supporting complete tumor resection as a prognostic determinant even in locally advanced cases.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Treatment outcomes of robot-assisted rectal cancer surgery with multivisceral resection of adjacent organs

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月30日

查看全文
  • Ayumi Takaoka,
  • Naoko Irie,
  • Aoi Sugino,
  • Hiroyasu Ishikawa,
  • Takehiro Shiraishi,
  • Tetsuya Ito,
  • Noriyasu Chika,
  • Toru Ishiguro,
  • Takatoshi Matsuyama,
  • Youichi Kumagai,
  • Hideyuki Ishida

摘要

Robotic surgery is increasingly adopted for rectal cancer management, including selected patients with locally advanced disease. We evaluated perioperative safety and medium- to long-term outcomes after robot-assisted rectal cancer surgery with multivisceral resection for cT4 rectal cancer in a single high-volume center. We retrospectively reviewed 45 consecutive patients with locally advanced rectal cancer who underwent robot-assisted surgery with multivisceral resection between April 2021 and June 2025. Demographic and clinical variables, surgical and postoperative outcomes, and pathological findings were extracted from medical records. Recurrence-free survival (RFS), overall survival, and local recurrence were assessed. The study included 45 patients (19 females) with a median age of 72 years. Postoperative complications of Clavien–Dindo grade III or higher occurred in 4 patients (8.8%). Pathologically, 21 patients (46.7%) had pT4 disease (pT4a in 2 and pT4b in 19 [42.2%]), and 39 patients (86.7%) achieved RM0 margins. The median follow-up was 23 months. Across stages I–III, RM0 resection was associated with superior 3-year RFS compared with RM1/RMX resection (74.6% vs. 33.3%, p = 0.03). Robot-assisted rectal cancer surgery combined with multivisceral resection can be performed safely, with acceptable midterm outcomes. RM0 status was linked to improved RFS, supporting complete tumor resection as a prognostic determinant even in locally advanced cases.